Selegiline Hydrochloride

CHEMBL1200904 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

223.7 g/mol

LogP

—

Phase

4

A hydrochloride salt form of selegiline with the same therapeutic properties. Used in the early stages of Parkinson's disease, this medication slows the breakdown of dopamine in the brain by inhibiting the MAO-B enzyme.

Moleküler Ağırlık

223,7400 g/mol

TPSA

3,20 Å²

Terapötik Alanlar

Parkinson's Disease Schizophrenia Major Depressive Disorder Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

C#CCN(C)[C@H](C)Cc1ccccc1.Cl

InChI

InChI=1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H/t12-;/m1./s1

Molecular Formula

C13H18ClN

HBD / HBA

1 / 1

Döndürülebilir Bağlar

4

Ağır Atomlar

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A hydrochloride salt form of selegiline with the same therapeutic properties. Used in the early stages of Parkinson's disease, this medication slows the breakdown of dopamine in the brain by inhibiting the MAO-B enzyme.

Yes, Selegiline Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200904. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 26758. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Selegiline Hydrochloride PillFYI'da

Yapı

Hızlı Veriler

Formül: C13H18ClN
Eş Anlamlılar: 2

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.